Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$13.06 USD
-0.27 (-2.03%)
Updated Apr 22, 2024 11:56 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Sage Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -541.49 | -532.78 | -457.89 | 606.07 | -680.24 |
Depreciation/Amortization & Depletion | -4.95 | 6.98 | 17.23 | 3.68 | -4.68 |
Net Change from Assets/Liabilities | -67.38 | 5.67 | -18.51 | -39.73 | 6.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 73.23 | 60.10 | 80.99 | 94.26 | 149.56 |
Net Cash From Operating Activities | -540.59 | -460.04 | -378.18 | 664.28 | -528.71 |
Property & Equipment | -0.55 | -0.94 | -0.37 | -0.35 | -5.75 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 443.47 | 326.37 | -1,002.08 | 443.03 | -137.41 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 442.91 | 325.43 | -1,002.45 | 442.68 | -143.16 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.93 | 3.11 | 14.72 | 426.76 | 610.13 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.90 | -0.04 | -1.39 | 0.00 | -2.50 |
Net Cash from Financing Activities | 6.03 | 3.07 | 13.33 | 426.76 | 607.62 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -91.65 | -131.53 | -1,367.30 | 1,533.73 | -64.24 |
Cash at Beginning of Period | 163.97 | 295.50 | 1,662.80 | 129.07 | 193.31 |
Cash at End of Period | 72.32 | 163.97 | 295.50 | 1,662.80 | 129.07 |
Diluted Net EPS | -9.05 | -8.98 | -7.80 | 11.43 | -13.38 |
Fiscal Year End for Sage Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -541.49 | -508.78 | -307.15 | -146.83 |
Depreciation/Amortization & Depletion | NA | -4.95 | -11.54 | -6.92 | -2.86 |
Net Change from Assets/Liabilities | NA | -67.38 | 38.90 | -2.79 | -24.01 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 73.23 | 60.35 | 31.66 | 20.01 |
Net Cash From Operating Activities | NA | -540.59 | -421.07 | -285.20 | -153.68 |
Property & Equipment | NA | -0.55 | -0.67 | -0.34 | -0.23 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 443.47 | 401.52 | 240.80 | 195.09 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 442.91 | 400.85 | 240.46 | 194.87 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 6.93 | 6.93 | 4.16 | 3.30 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.90 | -0.64 | -0.64 | -0.63 |
Net Cash from Financing Activities | NA | 6.03 | 6.29 | 3.52 | 2.67 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -91.65 | -13.93 | -41.22 | 43.86 |
Cash at Beginning of Period | NA | 163.97 | 163.97 | 163.97 | 163.97 |
Cash at End of Period | NA | 72.32 | 150.04 | 122.75 | 207.83 |
Diluted Net EPS | NA | -0.54 | -3.37 | -2.68 | -2.46 |